Among geriatric screening tools, ISAR was independently associated with discharge destination in older adults transferred from ED to intermediate care. Predictive validity was poor. Further research on selection of candidates for alternatives to conventional hospitalization is needed.

No abstract

Background The effectiveness of antiretroviral treatment depends on several factors. Incorrect adherence is the main cause of treatment failure and it has been related to an increase in mortality. Purpose To assess the compatibility of the recommendations for antiretroviral treatment administration with the recommendations in the product information. To discover the patients' adherence to the treatment. Materials and methods Prospective observational study, conducted over two weeks, in an outpatient pharmacy department of a community hospital that serves a total of 415 HIV patients. All the HIV patients that came to collect their treatment in the pharmacy department and agreed to collaborate in the study were included. The exclusion criteria were: patients who started or changed their treatment, if it was a relative who collected the treatment or because of a language barrier. A data collection sheet was designed, which included demographic information (gender, age), data related to antiretroviral therapy (which drugs, how and when they were taken) and the SMAQ (Simplified Medication Adherence Questionnaire) adherence test. Results 112 patients were interviewed. 76 of them were included in the study (78.95% (60) men, mean age 48). 40.80% (31) of patients did not follow the product information recommendations. The drugs with which more discrepancies were found were ritonavir (14.47%; 11) and efavirenz (17.11%; 13). Ritonavir was mainly taken on an empty stomach instead of being taken with meals. Efavirenz was taken with meals instead of being taken on an empty stomach as recommended in the product information. 39.47% (30) of patients were considered non-adherent according to the SMAQ adherence test. Conclusions These results confirm the need to include a pharmaceutical care programs for HIV patients. It would be advisable to inform them about their treatment prior to them starting it to achieve the maximum benefit and to improve the adherence to the treatment. Future studies with other adherence tests would be interesting in order to compare the results.

No abstract

Aim and objectives The objective of this study was to describe the current status of clinical trials (CT) for AD in our hospital pharmacy service and to analyse the investigational drugs. Material and methods An observational descriptive retrospective study was carried out in a tertiary academic hospital. All active CT in the neuropsychology service from 1 January 2014 to 31 March 2019 were reviewed. Collected data were total number of CT; total number of included patients; demographic data; total number of CT classified by CT status (active/closed); clinical trial phase; therapeutic targets (reduction of amyloid plaques (AP)/precursor amyloid peptide (PAP) attack/inhibition of GLYT1 transporter/selective antagonism of 5-HT6 receptor/partial selective agonism of a 7 nicotinic receptor); administration route (oral/intravenous/subcutaneous); clinical trials with results; and type of result (positive/negative). Results Twelve CT were analysed involving a total of 59 patients (mean 5 patients per clinical trial (rank 0-8)), 34 (57.6%) women with a mean age of 77.4 years (95% CI 71.5-84.7). Six (50.0%) CT were active; 3 (25.0%) CT were phase II trials and 9 (75.0%) were phase III trials. Therapeutic targets were reduction in AP 5 (41.7%), attack of PAP 3 (25.0%), inhibition of GLYT1 transporter 1 (8.3%), selective antagonism of 5-HT6 receptor 2 (16.7%), partial selective agonism of a 7 nicotinic receptor 1 (8.3%); route of administration oral 7 (58.3%), intravenous 1 (8.3%) or subcutaneous 4 (33.3%); and 3 (25.0%) CT had results, all of which were negative (3 (100%)). Conclusion and relevance. The highest number of active CT were phase III trials.. Only 25% of CT had results and all were negative.. Almost 60% of CT studied oral administration, which was patients' preference.. There were a total of five therapeutic targets but more than 40% of the CT evaluated the reduction in APs.. Based on these results, we should rethink the research on Alzheimer's disease before continuing to develop clinical trials with the same therapeutic target.